灵康药业: 可转债转股结果暨股份变动公告

Key Points - The core viewpoint of the announcement is the update on the conversion status of the company's convertible bonds, specifically the "Lingkang Convertible Bonds" and the impact on the company's share capital [1][2][3] Group 1: Convertible Bond Conversion Status - From January 1, 2025, to March 31, 2025, the amount converted from "Lingkang Convertible Bonds" was 6,000 RMB, resulting in 750 shares, which represents 0.0001% of the total shares before conversion [1][2] - As of March 31, 2025, a total of 67,196,000 RMB of "Lingkang Convertible Bonds" has been converted into company stock, amounting to 7,804,755 shares, which is 1.0940% of the total shares before conversion [1][2] - As of March 31, 2025, the amount of "Lingkang Convertible Bonds" that has not been converted, excluding those that have been repurchased, is 252,978,000 RMB, accounting for 48.1863% of the total issuance [3] Group 2: Issuance Overview - The company issued 5.25 million convertible bonds at a face value of 100 RMB each, with a total issuance amount of 525 million RMB, approved by the China Securities Regulatory Commission [1] - The bonds became convertible into the company's A-shares starting June 7, 2021, with a conversion price set at 8.00 RMB per share [2] - The company executed a buyback of 2,048,260 bonds from June 24 to June 28, 2024, with the repurchase funds distributed on July 3, 2024 [2]